Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Conference Participants

doi:10.1016/j.kint.2018.11.008

Management and treatment of glomerular diseases (part 2)

Standard

Management and treatment of glomerular diseases (part 2) : conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. / Conference Participants.

in: KIDNEY INT, Jahrgang 95, Nr. 2, 02.2019, S. 281-295.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Conference Participants 2019, 'Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference', KIDNEY INT, Jg. 95, Nr. 2, S. 281-295. https://doi.org/10.1016/j.kint.2018.11.008

APA

Conference Participants (2019). Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. KIDNEY INT, 95(2), 281-295. https://doi.org/10.1016/j.kint.2018.11.008

Vancouver

Conference Participants. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. KIDNEY INT. 2019 Feb;95(2):281-295. https://doi.org/10.1016/j.kint.2018.11.008

Bibtex

@article{ff933ed7c84d49758e1c6186d59a69d3,

title = "Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference",

abstract = "In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.",

keywords = "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications, Biomarkers/analysis, Consensus Development Conferences as Topic, Disease Progression, Genetic Testing, Glomerular Filtration Rate, Glomerulonephritis/etiology, Humans, Nephrology/methods, Nephrosis, Lipoid/etiology, Paraproteinemias/complications, Podocytes/immunology, Practice Guidelines as Topic, Risk Factors, Treatment Outcome",

author = "Rovin, {Brad H} and Caster, {Dawn J} and Cattran, {Daniel C} and Gibson, {Keisha L} and Hogan, {Jonathan J} and Moeller, {Marcus J} and Dario Roccatello and Michael Cheung and Wheeler, {David C} and Winkelmayer, {Wolfgang C} and J{\"u}rgen Floege and {Conference Participants}",

year = "2019",

month = feb,

doi = "10.1016/j.kint.2018.11.008",

language = "English",

volume = "95",

pages = "281--295",

journal = "KIDNEY INT",

issn = "0085-2538",

publisher = "NATURE PUBLISHING GROUP",

number = "2",

}

RIS

TY - JOUR

T1 - Management and treatment of glomerular diseases (part 2)

T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

AU - Rovin, Brad H

AU - Caster, Dawn J

AU - Cattran, Daniel C

AU - Gibson, Keisha L

AU - Hogan, Jonathan J

AU - Moeller, Marcus J

AU - Roccatello, Dario

AU - Cheung, Michael

AU - Wheeler, David C

AU - Winkelmayer, Wolfgang C

AU - Floege, Jürgen

AU - Conference Participants

PY - 2019/2

Y1 - 2019/2

N2 - In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.

AB - In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.

KW - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications

KW - Biomarkers/analysis

KW - Consensus Development Conferences as Topic

KW - Disease Progression

KW - Genetic Testing

KW - Glomerular Filtration Rate

KW - Glomerulonephritis/etiology

KW - Humans

KW - Nephrology/methods

KW - Nephrosis, Lipoid/etiology

KW - Paraproteinemias/complications

KW - Podocytes/immunology

KW - Practice Guidelines as Topic

KW - Risk Factors

KW - Treatment Outcome

U2 - 10.1016/j.kint.2018.11.008

DO - 10.1016/j.kint.2018.11.008

M3 - SCORING: Journal article

C2 - 30665569

VL - 95

SP - 281

EP - 295

JO - KIDNEY INT

JF - KIDNEY INT

SN - 0085-2538

IS - 2

ER -